File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Challenges in Measuring AMH in the Clinical Setting

TitleChallenges in Measuring AMH in the Clinical Setting
Authors
Keywordsanti-Müllerian hormone
enzyme-linked immunosorbent assay (ELISA)
automated chemiluminescence immunoassay
reference preparation
international standard
Issue Date2021
PublisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/endocrinology/
Citation
Frontiers in Endocrinology, 2021, v. 12, p. article no. 691432 How to Cite?
AbstractSerum anti-Mullerian hormone (AMH) is a widely used marker of functional ovarian reserve in the assessment and treatment of infertility. It is used to determine dosing of gonadotropins used for superovulation prior to in vitro fertilization, as well as to determine the degree of damage to ovarian reserve by cytotoxic treatments such as chemotherapy. AMH is also now used to predict proximity to menopause and potentially provides a sensitive and specific test for polycystic ovarian syndrome. Twenty one different AMH immunoassay platforms/methods are now commercially available. Of those compared, the random-access platforms are the most reliable. However, to date there has not been an agreed common international AMH reference preparation to standardize calibration between the various immunoassays. Recently, a purified human AMH preparation (code 16/190) has been investigated by the World Health Organization as a potential international reference preparation. However, this was only partially successful as commutability between it and serum samples was observed only in some but not all immunoassay methods. Development of a second generation reference preparation with wider commutability is proposed.
Persistent Identifierhttp://hdl.handle.net/10722/305931
ISSN
2023 Impact Factor: 3.9
2023 SCImago Journal Rankings: 1.240
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, RHW-
dc.contributor.authorRobertson, DM-
dc.contributor.authorBurns, C-
dc.contributor.authorLedger, WL-
dc.date.accessioned2021-10-20T10:16:23Z-
dc.date.available2021-10-20T10:16:23Z-
dc.date.issued2021-
dc.identifier.citationFrontiers in Endocrinology, 2021, v. 12, p. article no. 691432-
dc.identifier.issn1664-2392-
dc.identifier.urihttp://hdl.handle.net/10722/305931-
dc.description.abstractSerum anti-Mullerian hormone (AMH) is a widely used marker of functional ovarian reserve in the assessment and treatment of infertility. It is used to determine dosing of gonadotropins used for superovulation prior to in vitro fertilization, as well as to determine the degree of damage to ovarian reserve by cytotoxic treatments such as chemotherapy. AMH is also now used to predict proximity to menopause and potentially provides a sensitive and specific test for polycystic ovarian syndrome. Twenty one different AMH immunoassay platforms/methods are now commercially available. Of those compared, the random-access platforms are the most reliable. However, to date there has not been an agreed common international AMH reference preparation to standardize calibration between the various immunoassays. Recently, a purified human AMH preparation (code 16/190) has been investigated by the World Health Organization as a potential international reference preparation. However, this was only partially successful as commutability between it and serum samples was observed only in some but not all immunoassay methods. Development of a second generation reference preparation with wider commutability is proposed.-
dc.languageeng-
dc.publisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/endocrinology/-
dc.relation.ispartofFrontiers in Endocrinology-
dc.rightsThis Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectanti-Müllerian hormone-
dc.subjectenzyme-linked immunosorbent assay (ELISA)-
dc.subjectautomated chemiluminescence immunoassay-
dc.subjectreference preparation-
dc.subjectinternational standard-
dc.titleChallenges in Measuring AMH in the Clinical Setting-
dc.typeArticle-
dc.identifier.emailLi, RHW: raymondli@hku.hk-
dc.identifier.authorityLi, RHW=rp01649-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fendo.2021.691432-
dc.identifier.pmid34108942-
dc.identifier.pmcidPMC8183164-
dc.identifier.scopuseid_2-s2.0-85107435309-
dc.identifier.hkuros326638-
dc.identifier.volume12-
dc.identifier.spagearticle no. 691432-
dc.identifier.epagearticle no. 691432-
dc.identifier.isiWOS:000658413500001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats